Compare CubeSmart (CUBE) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs GSK plc — how do they compare? CubeSmart trades at $37.66 (market cap $8.45B), while GSK plc trades at $46.54 (market cap $91.88B). The key difference: GSK plc is far larger — about 10.9× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.65%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and GSK plc for 93 Days on average.
| CUBE | GSK | |
|---|---|---|
Market Cap | $8.45B | $91.88B |
Volume | 2,879,532 | 7,730,529 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $61.18 |
52-Week Low | $35.36 | $43.24 |
Typical Hold Time | 89 Days | 93 Days |
Enterprise Value | $11.97B | $111.88B |
Dividend Yield | 5.65% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CUBE trades at $37.23, down 1.4% on the day, with a bearish technical signal and mixed earnings history including a Q2 2026 FFO miss. The company maintains strong profitability with a 29.41% net income margin and a 5.4% dividend yield, but faces headwinds from moderating revenue growth and high leverage.
The outlook is cautiously optimistic with a consensus price target of $44.00, though risks include elevated debt levels and sector oversupply. Upside hinges on operational improvements and a return to earnings growth in H2 2026 as guided.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
